Inhibition of SHP2-mediated dephosphorylation of Ras suppresses oncogenesis
Open accessThe DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Abstract
Ras is phosphorylated on a conserved tyrosine at position 32 within the switch I region via Src kinase. This phosphorylation inhibits the binding of effector Raf while promoting the engagement of GTPase-activating protein (GAP) and GTP hydrolysis. Here we identify SHP2 as the ubiquitously expressed tyrosine phosphatase that preferentially binds to and dephosphorylates Ras to increase its association with Raf and activate downstream proliferative Ras/ERK/MAPK signalling. In comparison to normal astrocytes, SHP2 activity is elevated in astrocytes isolated from glioblastoma multiforme (GBM)-prone H-Ras(12V) knock-in mice as well as in glioma cell lines and patient-derived GBM specimens exhibiting hyperactive Ras. Pharmacologic inhibition of SHP2 activity attenuates cell proliferation, soft-agar colony formation and orthotopic GBM growth in NOD/SCID mice and decelerates the progression of low-grade astrocytoma to GBM in a spontaneous transgenic glioma mouse model. These results identify SHP2 as a direct activator of Ras and a potential therapeutic target for cancers driven by a previously ‘undruggable’ oncogenic or hyperactive Ras.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Blocking SHP2 prevents the loading of GTP into the RAS, and it is aimed to provide anticancer activity in this way [68,69].”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [68]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“SHP2 is a protein tyrosine phosphatase that promotes RAS signaling through multiple mechanisms, including facilitation of SOS1-mediated nucleotide exchange and regulation of KRAS conformational dynamics through dephosphorylation of Tyr32 and Tyr64 [8,9].”
From Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies (2026) · cites this paper as [9]
Experimental — accuracy not yet measuredIn the citing paper
“Src homology region 2 domain-containing phosphatase 2 (SHP2) is a receptor-free protein-tyrosine phosphatase and regulates proliferation by activating the RAS–MAPK–ERK signaling pathway.”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [68]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Glioma-Associated Cancer-Initiating Cells Induce Immunosuppression
Wei, J., Barr, J., Kong, L.-Y., Wang, Y., Wu, A., Sharma, A. K., Gumin, J., Henry, V., Colman, H., Sawaya, R., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1983 · Cited by 221
RetractedRETRACTED ARTICLE: Dynamin 2 mediates PDGFRα-SHP-2-promoted glioblastoma growth and invasion
Feng, H., Liu, K. W., Guo, P., Zhang, P., Cheng, T., McNiven, M. A., Johnson, G. R., Hu, B., & Cheng, S. (2011) · Oncogene · doi:10.1038/onc.2011.436 · Cited by 78
RetractedComprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Barbacid, M. (1987) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.56.070187.004023 · Cited by 3,885
Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome
Tartaglia, M., Mehler, E. L., Goldberg, R., Zampino, G., Brunner, H. G., Kremer, H., van der Burgt, I., Crosby, A. H., Ion, A., Jeffery, S., et al. (2001) · Nature Genetics · doi:10.1038/ng772 · Cited by 1,733
Ohh, M., Park, C. W., Ivan, M., Hoffman, M. A., Kim, T.-Y., Huang, L. E., Pavletich, N., Chau, V., & Kaelin, W. G. (2000) · Nature Cell Biology · doi:10.1038/35017054 · Cited by 1,577
Self-citationThe Ras-RasGAP Complex: Structural Basis for GTPase Activation and Its Loss in Oncogenic Ras Mutants
Scheffzek, K., Ahmadian, M. R., Kabsch, W., Wiesmüller, L., Lautwein, A., Schmitz, F., & Wittinghofer, A. (1997) · Science · doi:10.1126/science.277.5324.333 · Cited by 1,543
The Ras superfamily at a glance
Wennerberg, K., Rossman, K. L., & Der, C. J. (2005) · Journal of Cell Science · doi:10.1242/jcs.01660 · Cited by 1,352
Egan, S. E., Giddings, B. W., Brooks, M. W., Buday, L., Sizeland, A. M., & Weinberg, R. A. (1993) · Nature · doi:10.1038/363045a0 · Cited by 1,215
FUNCTION AND REGULATION OF RAS
Lowy, D. R., & Willumsen, B. M. (1993) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.62.070193.004223 · Cited by 1,186
Research works printed but not linked: 1
- Kirsten, W. H. & Mayer, L. A. Morphologic responses to a murine erythroblastosis virus. J. Natl Cancer Inst. 39, 311–335 (1967).
Cited by
Items 201–265 of 265
Regulatory role of protein tyrosine phosphatases in hematopoiesis and leukemogenesis
Wang, X., Guan, Y., Qin, Y., Guan, Z., Xu, G., Dong, Y., Lu, Z., Zhang, X., Zheng, L., & Zhou, Q. (2026) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2026.105033 · Cited by 1
Posttranslational modifications of RAS: few pockets but many bumps
Fissore-O'Leary, M., & Philips, M. R. (2026) · Biological Chemistry · doi:10.1515/hsz-2026-0102 · Cited by 1
“These authors went on to show that SHP2 dephosphorylates RAS at position 32 and thereby potentiates signaling (Bunda et al. 2015).”
Wang, S., Zhao, X., Dong, J. X., Zhang, J., Wang, Y., Jin, H., Jiang, X., Chen, L., Zhang, M., Ji, L., et al. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-08477-4 · Cited by 1
“Through its ability to transmit diverse upstream growth signals, SHP2 functions as a central signaling hub in multiple GI cancers, driving tumor proliferation and survival [28].”
Bruno, J. L., Merrin, J., Hosseini, S. M. H., & Green, T. (2025) · Developmental Medicine & Child Neurology · doi:10.1111/dmcn.16278 · Cited by 1
Xiao, Y., 郑一凡, Hua, Y., Peng, J., Liu, J., Qu, Y., Xu, J., Fu, R., Qian, Q., Košař, M., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.30.721835 · Cited by 1
Kano, Y. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27135796
Self-citationDiscovery of small molecule modulators of Ras superfamily proteins : Studies of MgcRacGAP and Ras
van Adrichem, A. J. (2016) · Helda - University of Helsinki Institutional Repository
Fragment-based screening of the oncogenic protein tyrosine phosphatase SHP2
Quill, L. (2017) · University of Birmingham Institutional Research Archive (University of Birmingham)
Role Of MIR-489 In HER2 Positive Breast Cancer
Patel, Y. K. (2018) · Scholar Commons (University of South Carolina)
Cao, M. (2018) · Padua@research (University of Padova)
Biomarker based therapies in high risk cancer patients - MACC1 as molecular target
Zincke, F. (2020) · edoc Publication server (Humboldt University of Berlin) · doi:10.18452/21021 · Cited by 1
Toral, K. (2021) · UKnowledge (University of Kentucky) · doi:10.13023/etd.2021.362
Lazo, J. S. (2018) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.727651712.793543398
Research Progress in Allosteric SHP2 Inhibitors
堵, 桐. (2022) · Hans Journal of Medicinal Chemistry · doi:10.12677/hjmce.2022.102021
Ruckert, M. T. (2022) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.17.2022.tde-09112022-122218
Sinnett‐Smith, J. W., Anwar, T., Reed, E. F., Teper, Y., Eibl, G., & Rozengurt, E. (2023) · doi:10.1158/1535-7163.c.6543589
Therapeutic Effect of Shp2 Inhibition Combined with Regorafenib in Advanced Colorectal CancerPreprint
Han, X., Wang, W., Zhang, W., Zhu, L., Xu, L., Li, X., Xu, Q., Guo, W., & Gu, Y. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4534174
Inhibition of RAS as a novel therapeutic approach in Luminal B breast cancer.
Jigo, R. (2023) · ThinkIR: The University of Louisville's Institutional Repository (University of Louisville) · doi:10.18297/etd/4150 · Cited by 1
Cui, H., Zhang, R., Xiong, X., Cui, Z., Min, Z., Liu, J.-L., Liu, J., & Min, Z.-L. (2024) · Current Computer - Aided Drug Design · doi:10.2174/0115734099285448240304072649
Decroocq, J. (2019) · theses.fr (ABES) · doi:10.70675/6e933875z3629z4e49z9d73z698f1f919e4c
Anand, A., Schömig, L. R., Lange, S., Tran, L., Flisikowski, K., Öllinger, R., Rad, R., Vieth, M. W., Steiger, K., Baumeister, T., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.05.07.592904
Zhang, J., Tan, Z., Qin, Q., Peng, H., Shi, W., Yu, H., & Dong, B. (2025) · Open Biology · doi:10.1098/rsob.240402
Recent advances in phosphatase drug discovery and development
LaMarche, M. J. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29808-0.00065-0
Discovery a plasiatine-based potent SHP2 activator as a potential anti-atherosclerotic agent
Ding, X., Geng, T., Li, Y., Pan, P., Li, Z., Li, Z., & Meng, X. (2025) · Chinese Chemical Letters · doi:10.1016/j.cclet.2025.112140
Liotti, F., Kumar, N., Prevete, N., Marotta, M., Sorriento, D., Ieranò, C., Ronchi, A., Marino, F. Z., Moretti, S., Colella, R., et al. (2021) · Figshare · doi:10.6084/m9.figshare.13544170
Self-citationLiotti, F., Kumar, N., Prevete, N., Marotta, M., Sorriento, D., Ieranò, C., Ronchi, A., Marino, F. Z., Moretti, S., Colella, R., et al. (2021) · Figshare · doi:10.6084/m9.figshare.13544158
Self-citationLiotti, F., Kumar, N., Prevete, N., Marotta, M., Sorriento, D., Ieranò, C., Ronchi, A., Marino, F. Z., Moretti, S., Colella, R., et al. (2021) · Figshare · doi:10.6084/m9.figshare.13544161
Self-citationWei, Q., Singh, O., Ekinci, C., Gill, J. K., Li, M., Mamatjan, Y., Karimi, S., Bunda, S., Mansouri, S., Aldape, K., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14418459
Self-citationLiotti, F., Kumar, N., Prevete, N., Marotta, M., Sorriento, D., Ieranò, C., Ronchi, A., Marino, F. Z., Moretti, S., Colella, R., et al. (2021) · Figshare · doi:10.6084/m9.figshare.13544164
Self-citationLiotti, F., Kumar, N., Prevete, N., Marotta, M., Sorriento, D., Ieranò, C., Ronchi, A., Marino, F. Z., Moretti, S., Colella, R., et al. (2021) · Figshare · doi:10.6084/m9.figshare.13544167
Self-citationLiotti, F., Kumar, N., Prevete, N., Marotta, M., Sorriento, D., Ieranò, C., Ronchi, A., Marino, F. Z., Moretti, S., Colella, R., et al. (2021) · Figshare · doi:10.6084/m9.figshare.13544173
Self-citationLee, H., & Lee, G. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.03.20.712775
“SHP2 (encoded by PTPN11), a tyrosine phosphatase that positively regulates RAS activation downstream of receptor tyrosine kinases, has emerged as a therapeutic target in EGFR-amplified TNBC, with allosteric SHP2 inhibitors entering clinical evaluation [5-7].”
CNKSR1はRhoB-GTPとの排他的な相互作用を介してEGFR脱リン酸化酵素を活性化する足場となる
西山, 加., & Nishiyama, K. (2022) · Institutional Repositories DataBase (IRDB)
Impact de la protéine SHP2 associé au syndrome de Noonan sur le métabolisme glucidique
Paccoud, R. (2018) · theses.fr (ABES) · doi:10.70675/f9b9b046zdf4bz404fz9689z8deb20f6e5ac
“(2007) Malignant melanoma in a woman with LEOPARD syndrome: identification of a germline PTPN11 mutation and a somatic BRAF mutation.”
BackgroundInfluentialEtude des anomalies du métabolisme énergétique associées au syndrome de Noonan
Branka, S. (2019) · theses.fr (ABES) · doi:10.70675/b0d081a3z3492z4457za237zcabd6ccc0a76
Mazeyrie, L. (2024) · theses.fr (ABES) · doi:10.70675/04dabd62z8f26z4393zac25z0070faaa4fb9
Nguyen, K. (2026) · Institutional Repositories DataBase (IRDB) · doi:10.15099/0002002225
Valencia-Sama, I., Kee, L., Weiss, A., Hayes, M. N., Ohh, M., & Irwin, M. S. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.24.734371
Self-citationGenetic and epigenetic modifiers of metastasis: Context matters
Welch, D. R., Swancutt, K. L., Walsh, R. M., & Fisette, G. (2026) · Quarterly Reviews of Biophysics · doi:10.1017/s0033583526100201
Dietrich, A., Lewitzky, M., Gruber, T., Balbach, J., Feller, S. M., & Weininger, U. (2026) · Biopolymers · doi:10.1002/bip.70120
“…tyrosines, Tyr 627 and Tyr 659, are both well-characterized docking sites for the tandem SH2 domains of the protein tyrosine phosphatase SHP2, a regulator of the Ras GTPase and its modulators [15, 16], mediating the activation of the Ras– MAPK signaling pathway and driving proliferation [17].”
Protein Tyrosine Phosphatases in Cancer: From Oncogenic Drivers to Therapeutic Targets
Perla, S., Pascale, J. V., Liu, M., Kumar, A., Kuppuswamy, S., Goud, A. C., & Samara, V. A. (2026) · Cells · doi:10.3390/cells15191767 · Cited by 2
“In case of breast cancer, leukemia and gliomas, SHP2 acts as an oncogene and dysregulates the EGFR/Ras/MAPK pathway [66–72].”
Xie, W., Tian, M., Ma, W., Sun, Y., Hu, L., Zeng, Y., Chen, X., Ruan, X., Zheng, X., & Gao, M. (2026) · Investigational New Drugs · doi:10.1007/s10637-026-01633-z
Le rôle de SHP-2 dans la transformation épithéliale intestinale induite par l’oncogène BRAF
Lamontagne, A. (2026) · Knowledge UdeS (Institutional Deposit of the University of Sherbrooke) · doi:10.71892/11143/1912
Jain, A., Kumar, R., Reddy, S. M., & Shankar, J. (2026) · BIO Web of Conferences · doi:10.1051/bioconf/202625204008
Jain, A., Kumar, R., Reddy, S. M., & Shankar, J. (2026) · Springer Link (Chiba Institute of Technology) · doi:10.1051/bioconf/202625204008/pdf
Wang, C., Zhang, Y., Bao, S., Huang, X., Wang, C., & Zhang, Y. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.110565
Sequence space exploration in SHP2: mechanistic insights from disease-associated mutations
van Vlimmeren, A. E., Jiang, Z., Semoy, D. A., & Shah, N. H. (2026) · Biochemical Journal · doi:10.1042/bcj20250266
BindingDB (2021) · UC San Diego · doi:10.7270/q2nz8c6f
BindingDB (2024) · UC San Diego · doi:10.7270/q2ww7nvc
BindingDB (2022) · UC San Diego · doi:10.7270/q2cc14bb
BindingDB (2025) · UC San Diego · doi:10.7270/q2hd81cs
BindingDB Entry 50009588: Optimization of Fused Bicyclic Allosteric SHP2 Inhibitors.
BindingDB (2021) · UC San Diego · doi:10.7270/q25t3pzd
BindingDB Entry 50022804: Advances in SHP2 tunnel allosteric inhibitors and bifunctional molecules.
BindingDB (2026) · UC San Diego · doi:10.7270/q2v98dw4
Metadata
- Authors
- Bunda, S., Burrell, K., Heir, P., Zeng, L., Alamsahebpour, A., Kano, Y., Raught, B., Zhang, Z.-Y., Zadeh, G., & Ohh, M.
- Affiliations
- University of Toronto (CA)
- University Health Network (CA)
- Princess Margaret Cancer Centre (CA)
- Indiana University Indianapolis (US)
- Corresponding author
- Ohh, Michael
- Venue
- Nature Communications
- Published
- 2015-11-30
- Volume
- 6
- Issue
- 1
- Pages
- 8859-8859
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC4674766
- OpenAlex
- W2254051095
- Cited by
- 249
- References
- 63
- Citations by year
- 2026: 20 · 2025: 21 · 2024: 29 · 2023: 36 · 2022: 30 · 2021: 30 · 2020: 17 · 2019: 20 · 2018: 15 · 2017: 21 · 2016: 10
- FWCI
- 6.65
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- IUScholarWorks (Indiana University) (submittedVersion, cc-by)
- PMC
- Funders
- National Institutes of Health
- Canadian Institutes of Health Research
- National Cancer Institute (R01CA69202, R01CA069202)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Keywords
- SHP2, protein tyrosine phosphatase, Raf activation, glioblastoma, astrocytes, oncogenic Ras, therapeutic target, cell proliferation, tumor growth
- MeSH terms
- Animals, Cell Line, Female, Glioblastoma, Humans, Male, Mice, Inbred ICR, Phosphorylation, Oncogene Protein p21(ras), Mice, SCID, Mice, Inbred NOD, Mice, Knockout, Mice, Protein Tyrosine Phosphatase, Non-Receptor Type 11, Carcinogenesis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.